This trial is active, not recruiting.

Condition glaucoma, angle-closure
Treatment topiramate
Phase phase 4
Sponsor Chinese University of Hong Kong
Collaborator Hong Kong Eye Hospital
Start date September 2004
End date July 2007
Trial size 15 participants
Trial identifier NCT00153699, CRE-2004.310, NCT00518063


We test the hypothesis whether topiramate narrows the angles which may render Asians more likely to suffer from acute angle closure glaucoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Change(s) in ophthalmic parameters measured at baseline and after 4 weeks of treatment, including:
time frame: 4 weeks
best-corrected visual acuity, refraction, Goldmann applanation tonometry, Gonioscopy, dilated fundus examination,
time frame: 4 weeks
and ultrasound biomicroscopy of angle and anterior segment.
time frame: 4 weeks

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Participants aged 18-75 with an indication for starting topiramate. Exclusion Criteria: - Patients with known allergy or intolerance to topiramate. - Recent exposure to topiramate (<3 months). - Moderate to severe renal failure. - Known history of renal calculi or hepatic failure - Inability to give informed consent. - Pregnant women or women of child-bearing age who do not practise an acceptable means of contraception. - Patients known to have angle-closure glaucoma.

Additional Information

Official title Relationship Between Topiramate Use and Ocular Angle Status: A Prospective Pilot Study
Principal investigator Dexter YL Leung, MRCS
Description Topiramate is approved for the treatment of epilepsy and prophylaxis of migraine attacks. There were case reports of acute angle closure glaucoma (AACG) associated with its use. AACG is particularly common in Asians because of a higher prevalence of narrow angle., we test the hypothesis whether topiramate narrows the angles which may render them more likely to suffer from AACG.
Trial information was received from ClinicalTrials.gov and was last updated in October 2007.
Information provided to ClinicalTrials.gov by Chinese University of Hong Kong.